Running a NAMS wheel strategy lets you generate consistent premium income on NewAmsterdam Pharma Company NV while setting your own entry and exit prices on the underlying. NewAmsterdam Pharma Company NV's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own NAMS, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best NAMS wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on NAMS, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable NAMS wheel from a losing one.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the NAMS wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your NAMS wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
